miR-200c inhibits metastasis of breast cancer cells by targeting HMGB1

  • Bao-ping Chang (常保萍)
  • Dong-sheng Wang (王东生)
  • Jian-wu Xing (邢建武)
  • Shao-hua Yang (杨少华)
  • Qian Chu (褚 倩)
  • Shi-ying Yu (于世英)Email author


miR-200c has been shown to regulate the epithelial-mesenchymal transition (EMT) by inhibiting ZEB1 and ZEB2 expression in breast cancer cells. This study further examined the role of miR-200c in the invasion and metastasis of breast cancer that goes beyond the regulation on ZEB1 and ZEB2 expression. In this study, the bioinformatics software (miRanda) was used to predict the target gene of miR-200c and Renilla luciferase assay to verify the result. The metastatic breast cancer cells MDA-MB-231 were cultured and transfected with the miR-200c mimic or inhibitor. The expressions of miR-200c and HMGB1 were detected by RT-PCR and Western blotting, respectively. Transwell assay and wound healing assay were employed to examine the invasive and migrating ability of transfected cells. Target prediction and Renilla luciferase analysis revealed that HMGB1 was a putative target gene of miR-200c. After transfection of MDA-MB-231 cells with the miR-200c mimic or inhibitor, the expression of miR-200c was significantly increased or decreased when compared with cells transfected with the miR-200c mimic NC or inhibitor NC. Moreover, the expression of HMGB1 was reversely correlated with that of miR-200c in transfected cells. Tranwell assay showed that the number of invasive cells was significantly reduced in miR-200c mimic group when compared with miR-200c inhibitor group. It was also found that the migrating ability of cells transfected with miR-200c mimics was much lower than that of cells transfected with miR-200c inhibitors. It was suggested that miR-200c can suppress the invasion and migration of breast cancer cells by regulating the expression of HMGB1. miR-200c and HMGB1 may become useful biomarkers for progression of breast cancer and targets of gene therapy.

Key words

breast cancer miR-200c HMGB1 metastasis 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin, 2013,63(1):11–30PubMedCrossRefGoogle Scholar
  2. 2.
    Jiang P, Enomoto A, Takahashi M. Cell biology of the movement of breast cancer cells: intracellular signaling and the actin cytoskeleton. Cancer Lett, 2009,284(2):122–130PubMedCrossRefGoogle Scholar
  3. 3.
    Graves P, Zeng Y. Biogenesis of mammalian microRNAs: a global view. Genomics Proteomics Bioinformatics, 2012,10(5):239–245PubMedCrossRefGoogle Scholar
  4. 4.
    Macfarlane LA, Murphy PR. MicroRNA: biogenesis, function and role in cancer. Curr Genomics, 2010,11(7):537–561PubMedCentralPubMedCrossRefGoogle Scholar
  5. 5.
    Burk U, Schubert J, Wellner U, et al. A reciprocal repression between ZEB1 and members of the miR-200 family promotes EMT and invasion in cancer cells. EMBO Rep, 2008,9(6):582–589PubMedCentralPubMedCrossRefGoogle Scholar
  6. 6.
    Peter ME. Let-7 and miR-200 microRNAs: guardians against pluripotency and cancer progression. Cell Cycle, 2009,8(6):843–852PubMedCentralPubMedCrossRefGoogle Scholar
  7. 7.
    Shimono Y, Zabala M, Cho RW, et al. Downregulation of miRNA-200c links breast cancer stem cells with normal stem cells. Cell, 2009,138(3):592–603PubMedCentralPubMedCrossRefGoogle Scholar
  8. 8.
    Schickel R, Park SM, Murmann AE, et al. mir-200c regulates induction of apoptosis through CD95 by targeting FAP-1. Mol Cell, 2010,38(6):908–915PubMedCentralPubMedCrossRefGoogle Scholar
  9. 9.
    Chang CJ, Chao CH, Xia W, et al. p53 regulates epithelial-mesenchymal transition and stem cell properties through modulating miRNAs. Nat Cell Biol, 2011,13(3):317–323PubMedCentralPubMedCrossRefGoogle Scholar
  10. 10.
    Cochrane DR, Spoelstra NS, Howe EN, et al. MicroRNA-200c mitigates invasiveness and restores sensitivity to microtubule-targeting chemotherapeutic agents. Mol Cancer Ther, 2009,8(5):1055–1066PubMedCrossRefGoogle Scholar
  11. 11.
    Lin J, Liu C, Gao F, et al. miR-200c enhances radiosensitivity of human breast cancer cells. J Cell Biochem, 2013,114(3):606–615PubMedCrossRefGoogle Scholar
  12. 12.
    Ahmad A, Aboukameel A, Kong D, et al. Phosphoglucose isomerase/autocrine motility factor mediates epithelial-mesenchymal transition regulated by miR-200 in breast cancer cells. Cancer Res, 2011,71(9):3400–3409PubMedCentralPubMedCrossRefGoogle Scholar
  13. 13.
    Howe EN, Cochrane DR, Cittelly DM, et al. miR-200c targets a NF-κB up-regulated TrkB/NTF3 autocrine signaling loop to enhance anoikis sensitivity in triple negative breast cancer. PLoS One, 2012,7(11):e49987PubMedCentralPubMedCrossRefGoogle Scholar
  14. 14.
    Jurmeister S, Baumann M, Balwierz A, et al. MicroRNA-200c represses migration and invasion of breast cancer cells by targeting actin-regulatory proteins FHOD1 and PPM1F. Mol Cell Biol, 2012,32(3):633–651PubMedCentralPubMedCrossRefGoogle Scholar
  15. 15.
    Chen Y, Sun Y, Chen L, et al. miRNA-200c increases the sensitivity of breast cancer cells to doxorubicin through the suppression of E-cadherin-mediated PTEN/Akt signaling. Mol Med Rep, 2013,7(5):1579–1584PubMedGoogle Scholar
  16. 16.
    Nikoletopoulou V, Markaki M, Palikaras K, et al. Crosstalk between apoptosis, necrosis and autophagy. Biochim Biophys Acta, 2013,1833(12):3448–3459PubMedCrossRefGoogle Scholar
  17. 17.
    Ko YB, Kim BR, Nam SL, et al. High-mobility group box 1 (HMGB1) protein regulates tumor-associated cell migration through the interaction with BTB domain. Cell Signal, 2014,26(4):777–783PubMedCrossRefGoogle Scholar
  18. 18.
    Tang D, Kang R, Zeh HJ 3rd, et al. High-mobility group box 1 and cancer. BBA, 2010,1799(1–2):131–140PubMedCentralPubMedGoogle Scholar
  19. 19.
    Sparatore B, Patrone M, Passalacqua M, et al. Activation of A431 human carcinoma cell motility by extracellular high-mobility group box 1 protein and epidermal growth factor stimuli. Biochem J, 2005,389(1):215–221PubMedCentralPubMedCrossRefGoogle Scholar
  20. 20.
    Brezniceanu ML, Völp K, Bösser S, et al. HMGB1 inhibits cell death in yeast and mammalian cells and is abundantly expressed in human breast carcinoma. FASEB J, 2003,17(10):1295–1297PubMedGoogle Scholar
  21. 21.
    Livesey KM, Kang R, Vernon P, et al. p53/HMGB1 complexes regulate autophagy and apoptosis. Cancer Res, 2012,72(8):1996–2005PubMedCentralPubMedCrossRefGoogle Scholar
  22. 22.
    van Beijnum JR, Nowak-Sliwinska P, van den Boezem E, et al. Tumor angiogenesis is enforced by autocrine regulation of high-mobility group box 1. Oncogene, 2013,32(3):363–374PubMedCrossRefGoogle Scholar
  23. 23.
    Jiao Y, Wang HC, Fan SJ. Growth suppression and radiosensitivity increase by HMGBI in breast cancer. Acta pharmacologica Sinica, 2007,28(12):1957–1967PubMedCrossRefGoogle Scholar
  24. 24.
    Bernardini M, Lee CH, Beheshti B, et a1. High-resolution mapping of genomic imbalance and identification of gene expression profiles associated with differential chemotherapy response in serous epithelial ovarian cancer. Neoplasia, 2005,7(6):603–613PubMedCentralPubMedCrossRefGoogle Scholar
  25. 25.
    Barnes KR, Kutikov A, Lippard SJ. Synthesis, characterization, and cytotoxicity of a series of estrogen-tethered platinum (IV) complexes. Chem Biol, 2004,11(4):557–564PubMedCrossRefGoogle Scholar
  26. 26.
    Gregory PA, Bracken CP, Smith E, et al. An autocrine TGF-beta/ZEB/miR-200 signaling network regulates establishment and maintenance of epithelial-mesenchymal transition. Mol Biol Cell, 2011,22(10):1686–1698PubMedCentralPubMedCrossRefGoogle Scholar
  27. 27.
    Tobar N, Villar V, Santibanez JF. ROS-NFkappaB mediates TGF-beta1-induced expression of urokinase-type plasminogen activator, matrix metalloproteinase-9 and cell invasion. Mol Cell Biochem, 2010,340(1–2):195–202PubMedCrossRefGoogle Scholar
  28. 28.
    Chua HL, Bhat-Nakshatri P, Clare SE. NF-kappaB represses E-cadherin expression and enhances epithelial to mesenchymal transition of mammary epithelial cells: potential involvement of ZEB-1 and ZEB-2. Oncogene, 2007,26(5):711–724PubMedCrossRefGoogle Scholar
  29. 29.
    Wu X, Mi Y, Yang H, et al. The activation of HMGB 1 as a progression factor on inflammation response in normal human bronchial epithelial cells through RAGE/JNK/NF-κB pathway, Mol Cell Biochem, 2013,380(1–2):249–257PubMedCrossRefGoogle Scholar
  30. 30.
    Smolarczyk R, Cichoń T, Jarosz M, et al. HMGB1—its role in tumor progression and anticancer therapy. Postepy Hig Med Dosw, 2012,22(66):913–920CrossRefGoogle Scholar

Copyright information

© Huazhong University of Science and Technology and Springer-Verlag Berlin Heidelberg 2014

Authors and Affiliations

  • Bao-ping Chang (常保萍)
    • 1
    • 2
  • Dong-sheng Wang (王东生)
    • 2
  • Jian-wu Xing (邢建武)
    • 2
  • Shao-hua Yang (杨少华)
    • 3
  • Qian Chu (褚 倩)
    • 1
  • Shi-ying Yu (于世英)
    • 1
    Email author
  1. 1.Department of Oncology, Tongji Hospital, Tongji Medical CollegeHuazhong University of Science and TechnologyWuhanChina
  2. 2.Department of OncologyThe Second Affiliated Hospital of Henan University of Science and TechnologyLuoyangChina
  3. 3.KingMed DiagnosticsZhengzhouChina

Personalised recommendations